Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens

OBJECTIVE: To determine whether a low dosage (0.3 mg/day) of unopposed conjugated estrogens can be used without incurring an elevated risk of endometrial cancer. METHODS: In this case-control study, cases (n = 484) consisted of women diagnosed with endometrial cancer between 1985 and 1991 in three counties in Western Washington. Controls (n = 780) were identified using random digit dialing within the same three counties. Subjects were interviewed in person to obtain basic demographic and medical history information, as well as specific information about hormone use. RESULTS: Eighteen cases and eight controls had taken 0.3 mg/day of unopposed conjugated estrogens and no other dose or preparation of estrogens (risk relative to that of women who had not taken postmenopausal hormones = 5.4, 95% confidence interval [CI] 2.3, 13.0). The risk was particularly high in women whose use of this dose was both current and of more than 8 years' duration (odds ratio = 9.2, 95% CI 2.9, 29.0). The elevation in risk in users of 0.3 mg/day was similar in size to that associated with the daily unopposed use of 0.625 mg of conjugated estrogens. CONCLUSION: The results suggest that a dosage of 0.3 mg per day of unopposed conjugated estrogens is associated with an increased risk of endometrial cancer.

This article has been cited by other articles:

				S. L. Deming, W. Zheng, W.-H. Xu, Q. Cai, Z. Ruan, Y.-B. Xiang, and X.-O. Shu UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 563 - 570. [Abstract] [Full Text] [PDF]

				S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]

				W. Y. Chen, J. E. Manson, S. E. Hankinson, B. Rosner, M. D. Holmes, W. C. Willett, and G. A. Colditz Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med, May 8, 2006; 166(9): 1027 - 1032. [Abstract] [Full Text] [PDF]

				B. Ettinger, K. E. Ensrud, R. Wallace, K. C. Johnson, S. R. Cummings, V. Yankov, E. Vittinghoff, and D. Grady Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial Obstet. Gynecol., September 1, 2004; 104(3): 443 - 451. [Abstract] [Full Text] [PDF]

				G. E. Hale, C. L. Hughes, and J. M. Cline Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15. [Abstract] [Full Text] [PDF]

				T. L. Bush, M. Whiteman, and J. A. Flaws Hormone Replacement Therapy and Breast Cancer: A Qualitative Review Obstet. Gynecol., September 1, 2001; 98(3): 498 - 508. [Abstract] [Full Text] [PDF]

				B. Ettinger, A. Pressman, and A. Van Gessel Low-Dosage Esterified Estrogens Opposed by Progestin at 6-Month Intervals Obstet. Gynecol., August 1, 2001; 98(2): 205 - 211. [Abstract] [Full Text] [PDF]

				K M Feeley and M Wells Hormone replacement therapy and the endometrium J. Clin. Pathol., June 1, 2001; 54(6): 435 - 440. [Abstract] [Full Text] [PDF]

				S. E. McNagny Prescribing Hormone Replacement Therapy for Menopausal Symptoms Ann Intern Med, October 19, 1999; 131(8): 605 - 616. [Abstract] [Full Text] [PDF]

				R. R. Recker, K. M. Davies, R. M. Dowd, and R. P. Heaney The Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women: A Randomized, Controlled Trial Ann Intern Med, June 1, 1999; 130(11): 897 - 904. [Abstract] [Full Text] [PDF]

				K. M. Prestwood, D. L. Thompson, A. M. Kenny, M. J. Seibel, C. C. Pilbeam, and L. G. Raisz Low Dose Estrogen and Calcium Have an Additive Effect on Bone Resorption in Older Women J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 179 - 183. [Abstract] [Full Text]